Open AccessIntracoronary allogeneic cardiosphere‐derived stem cells are safe for use in dogs with dilated cardiomyopathy
Author(s) -
Hensley Michael Taylor,
Tang Junnan,
Woodruff Kathleen,
Defrancesco Teresa,
Tou Sandra,
Williams Christina M.,
Breen Mathew,
Meurs Kathryn,
Keene Bruce,
Cheng Ke
Publication year - 2017
Publication title -
journal of cellular and molecular medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.44
H-Index - 130
eISSN - 1582-4934
pISSN - 1582-1838
DOI - 10.1111/jcmm.13077
Subject(s) - dilated cardiomyopathy , medicine , myocardial infarction , cd90 , adverse effect , cardiomyopathy , cardiology , stem cell , heart failure , biology , cd34 , genetics
Cardiosphere‐derived cells ( CDC s) have been shown to reduce scar size and increase viable myocardium in human patients with mild/moderate myocardial infarction. Studies in rodent models suggest that CDC therapy may confer therapeutic benefits in patients with non‐ischaemic dilated cardiomyopathy ( DCM ). We sought to determine the safety and efficacy of allogeneic CDC in a large animal (canine) model of spontaneous DCM . Canine CDCs (cCDCs) were grown from a donor dog heart. Similar to human CDC s, cCDC s express CD 105 and are slightly positive for c‐kit and CD 90. Thirty million of allogeneic cCDC s was infused into the coronary vessels of Doberman pinscher dogs with spontaneous DCM. Adverse events were closely monitored, and cardiac functions were measured by echocardiography. No adverse events occurred during and after cell infusion. Histology on dog hearts (after natural death) revealed no sign of immune rejection from the transplanted cells.